首页> 外文会议>International Symposium on Cancer Metastasis and the Lymphovascular system: Basis for Rational Therapy >T_(reg), Chemokines, and Other Small Molecules! Role In Metastasis and Its Prevention Experiences in Melanoma Immunobiology
【24h】

T_(reg), Chemokines, and Other Small Molecules! Role In Metastasis and Its Prevention Experiences in Melanoma Immunobiology

机译:T_(reg),趋化因子和其他小分子!转移中的作用及其在黑色素瘤免疫学中的预防经验

获取原文

摘要

It has long been known that malignant tumors contain variable numbers of lymphocytes referred to as tumor-infiltrating lymphocytes (TIL). In melanoma, the intensity of this lymphocytic infiltrate is correlated with outcome measures, though there is some debate in the literature that such an association may only exist for certain melanomas, for example, of a certain thickness. However, early studies on melanoma TIL did not immunophenotype these cells, and recent data have revealed that the composition of the tumoral lymphocytic infiltrate is not homogenous, but rather represents varying contributions from many lymphocytic subsets. Furthermore, the function of CD8 TIL is often compromised as a result of the accumulation of immunoregulatory cells and various tumor escape mechanisms. Nevertheless, the increase in our understanding of immunobiology has facilitated the development of logical immunother-apeutic strategies to overcome such hurdles. Examples of these strategies which are currently being tested in clinical trials and which are discussed in-depth include blocking antibodies against CTLA-4 and therapies to deplete Foxp3~+ regulatory T cells (T_(reg)), which will hopefully enhance existing immunotherapeutical protocols such as tumor immunization. In addition to strategies designed to tip the balance between antitumor immunity and regulatory T-cell function, a greater understanding of the small molecules which govern the migration of immunocytes and tumor cells (chemokines) has made possible the development of strategies to selectively impede certain immunocyte populations into the tumor microenvironment, as well as to abrogate the chemokine-mediated metastasis of tumor cells. This chapter highlights some of these current developments occurring in the field of immunological cancer therapy, and illustrates how these developments resulted from a greater understanding of basic immunobiology.
机译:人们早已知道,恶性肿瘤包含称为肿瘤浸润淋巴细胞(TIL)的淋巴细胞的可变数目。在黑色素瘤,此淋巴细胞浸润的强度与结果的措施相关,虽然有在文献中,这样的关联可以只存在某些黑素瘤,例如具有一定厚度的一些争论。然而,对黑色素瘤TIL早期的研究没有免疫表型这些细胞,并且最近的数据表明,肿瘤淋巴细胞浸润的组成不是同质的,而是代表了许多淋巴细胞亚群的不同贡献。此外,CD8 TIL的功能常常受到损害作为免疫调节细胞和各种肿瘤逃逸机制的积累的结果。然而,在我们的免疫生物学的理解增加了便利的逻辑immunother-apeutic发展战略,以克服这些障碍。这是目前在临床试验中进行测试,并且这些策略的例子在深入讨论的包括阻断抗体针对CTLA-4和疗法耗尽的Foxp3 +调节性T细胞(T_(REG)),其将有希望增强现有的免疫治疗协议如肿瘤免疫。除了设计成倾斜的抗肿瘤免疫和调节性T细胞的功能之间的平衡策略,更好地理解支配免疫细胞和肿瘤细胞(趋化因子)的迁移的小分子已经成为可能的策略的开发,以选择性地阻碍某些免疫细胞种群入肿瘤微环境,以及废除肿瘤细胞的趋化因子介导的转移。本章重点介绍一些在免疫癌症治疗领域出现的这些最新发展,并说明这些发展是如何导致从基本的免疫生物学更深入的了解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号